Advanced Cell Technology, a biotechnology company applying cellular technology in the emerging field of regenerative medicine, announced the signing of a clinical trial agreement with Chandler Regional Medical Center and Mercy Gilbert Medical Center – who are members of the Catholic Healthcare West (CHW), the eighth largest hospital system in the nation – to become ACT’s first clinical trial sites for Phase II myoblast study.
ACT and CHW announced in November 2007 that they had entered into a letter of intent for a proposed exclusive business arrangement to establish the clinical trial research site for the Phase II clinical trial. This study will soon be open for enrollment and will use 3 Dimensional Guided Catheter Based Delivery of Autologous Skeletal Myoblasts for Ishemic Cardiomyopathy.
The director of Cardiovascular Research for Chandler Regional Medical Center and Mercy Gilbert Medical Center will lead the enrollment in the CAuSMIC trial and will focus on patients who are not eligible for angioplasty or coronary artery bypass surgery.
William M. Coldwell, IV Chairman and CEO of ACT said, “The agreement with CHW signifies our readiness to begin the Phase II clinical trial. We are excited to begin the trial, which has the potential to be a major advance for the field of regenerative medicine and, more importantly, to patients in need of care. We look forward to working with such a prominent healthcare group.”
David G. Covert, President and CEO of the CHW East Valley Service Area and Chandler Regional Medical Center said, “Currently, there are no treatment options available to correct heart failure, only those that can slow its progression.”
Let us hear your thoughts below:
